|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 278, Issue 29, 26765-26772, July 18, 2003
Inhibition of Human Papillomavirus DNA Replication by Small Molecule Antagonists of the E1-E2 Protein Interaction*![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ¶
From the
Human papillomavirus (HPV) DNA replication is initiated by recruitment of
the E1 helicase by the E2 protein to the viral origin. Screening of our
corporate compound collection with an assay measuring the cooperative binding
of E1 and E2 to the origin identified a class of small molecule inhibitors of
the protein interaction between E1 and E2. Isothermal titration calorimetry
and changes in protein fluorescence showed that the inhibitors bind to the
transactivation domain of E2, the region that interacts with E1. These
compounds inhibit E2 of the low risk HPV types 6 and 11 but not those of high
risk HPV types or of cottontail rabbit papillomavirus. Functional evidence
that the transactivation domain is the target of inhibition was obtained by
swapping this domain between a sensitive (HPV11) and a resistant (cottontail
rabbit papillomavirus) E2 type and by identifying an amino acid substitution,
E100A, that increases inhibition by
Received for publication, April 7, 2003 * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ¶ To whom correspondence should be addressed: Dept. of Biological Sciences, Boehringer Ingelheim Ltd., 2100 Cunard St., Laval H7S 2G5, Canada. Tel.: 450-682-4640; Fax: 450-682-4642; E-mail: jarchambault{at}lav.boehringer-ingelheim.com.
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||